Author Archives: KIYATEC

  • 0

KIYATEC 3DKUBE® Featured in Tufts Publication

Tags : 


The 3DKUBE® perfusion bioreactor from KIYATEC was recently featured in the article entitled “Long term perfusion system supporting adipogenesis”

GREENVILLE, SC | April 2, 2015 – KIYATEC Inc. is pleased to announce that our 3DKUBE® perfusion bioreactor system was used to enable long term, in vitro viability and adipogenesis by researchers at Tufts University.  The article highlights the key advantages of 3D perfusion cell culture versus standard 2D and perfused 2D cell culture methods in creating adipogenic cells from preadipocyte cultures.

The work was authored by Rosalyn D. Abbott et al and results from many years of research into 3D perfusion cell culture techniques in the labs of David Kaplan at Tufts University.  The article may be purchased online at:

Key highlights of the research include:

• 2D and 3D perfusion culture techniques supported adipogenesis of preadipocytes.
• 3D perfusion contained adipocytes that were lost in the 2D perfused cultures.
• 3D perfusion stimulated greater lipogenesis and lipolysis compared to 2D perfusion.
• 3D perfusion stimulated decreased amounts of LDH compared to 2D perfusion.
• Greater glycerol was secreted with perfusion versus static cultures.

  • 0

$2M NCI Contract To Advance Predictive Cancer Diagnostics

Tags : 

National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics

Contract Funds 3D Breast Cancer, 3D Brain Cancer Micro-Tumor Development

GREENVILLE, SC | September 18, 2014 – KIYATEC announced today that it has been awarded a $1.975 million, Small Business Innovation Research (SBIR) Phase II Contract from the National Cancer Institute (NCI), one of the 27 institutes and centers that comprise the National Institutes of Health (NIH). Over the course of the two year award, KIYATEC will expand its 3D breast cancer model to address two issues at the forefront of cancer therapy strategies: 1) cancer’s interaction with the patient’s immune system (immuno-oncology) and 2) cancer’s interaction with the patient’s blood supply (angiogenesis). The award will also allow KIYATEC to broaden its technology platform beyond its current use in primary ovarian cancer and breast cancer testing and into glioblastoma multiforme (GBM), a type of brain cancer with a five year survival rate that is less than 10 percent. The funded contract has the potential to radically change the future of cancer patient care.

Predictive 3D Cancer Diagnostics